CPL is focused on the development and commercial manufacturing of non-sterile liquid and semi-solid pharmaceuticals 

Development

  • New formula development and re-formulation
  • Process optimization and qualification
  • Clinical trial supplies manufacturing
  • Technology transfer and scale-up
  • ANDA, NDA, 505(b)2 product development expertise

MANUFACTURING

  • Solutions, suspensions, sprays, lotions, gels, creams, ointments 
  • Hormone and corticosteroid products
  • Flammable material processing
  • Batch sizes up to 5,000Kg
  • Light and oxygen sensitive materials

PACKAGING

  • Bottles and jars
  • Tubes and sachets
  • Nasal sprays

TESTING

  • Analytical testing
  • Microbiology testing
  • ICH stability management
  • In-Vitro Release Testing (GMP)
  • Method development and qualification
  • Elemental Impurities Testing

Contact us

905.821.7600 

Go to article: Home | Covid-19 and the anti-vax movementGo to article: In this issueGo to article: ContentsGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Mettler Toledo Company InsightGo to article: Mettler ToledoGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: PuroliteGo to article: VEGA AustraliaGo to article: Gerteis Company Insight Go to article: GerteisGo to article: CommentGo to article: US election: Trump and Biden's priorities in the Covid-19 responseGo to article: Covid-19 disruption to trials declines, but recruitment is slowGo to article: Covid-19 vaccine developments across the globeGo to article: Eli Lilly and Regeneron’s EUA bids trigger concerns over available Covid-19 dataGo to article: AstraZeneca’s quick Covid-19 vaccine trial restart splits opinionGo to article: Q&A: Atomwise’s journey from discoverer to developerGo to article: Pfeiffer VacuumGo to article: Koehler eClinicalGo to article: Phoenix Company Insight Go to article: PhoenixGo to article: In DepthGo to article: How to combat vaccine hesitancy in the age of Covid-19Go to article: How Covid-19 has put clinical research’s diversity problem in the spotlight Go to article: No need for animal testing: improving vaccine research with GenoskinGo to article: Gout: drug development for an age-old diseaseGo to article: Treating chronic primary pain in the UKGo to article: Breast cancer breakthrough: could a new therapy silence stubborn TNBC?Go to article: Is quantum computing pharma's next big disruptor?Go to article: MimotopesGo to article: OptelGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: IWA Consulting Company Insight Go to article: IWA consultingGo to article: Nipro pharmapackagingGo to article: SwiftpakGo to article: EventsGo to article: Next issue